Lineage Cell Therapeutics
LCTX
LCTX
97 hedge funds and large institutions have $52.9M invested in Lineage Cell Therapeutics in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 27 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
33% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 27
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
Holders
97
Holding in Top 10
3
Calls
$138K
Puts
–
Top Buyers
| 1 | +$438K | |
| 2 | +$267K | |
| 3 | +$141K | |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$124K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$118K |
Top Sellers
| 1 | -$190K | |
| 2 | -$138K | |
| 3 | -$84.9K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$84.6K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$83.9K |